A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

Mok, Tony; Zee, Benny; Chan, Anthony T.C.; Park, Yeon Hee; Yang, Wei Tse; Yim, Anthony P.C.; Leung, Sing Fai; Nguyen, Binh Thanh; Leung, TW; Johnson, Philip J.

doi:10.1002/1097-0142(20000801)89:3<543::aid-cncr9>3.0.co;2-v

Cited by 16 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis B reactivation occurred in 20% of 78 carriers in a prospective study . Two patients developed severe hepatitis B reactivation in 46 stage IIIB/IV NSCLC patients who received gemcitabine and oral etoposide (Mok et al, 2000). The use of steroid in chemotherapy may contribute to hepatitis B reaction.…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

et al. 2002

View full text Add to dashboard Cite

The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m 72 , days 1, 8, 15) and cisplatin (90 mg m 72 , day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Reactivation of hbv has also been reported in other solid tumours, including hepatocellular carcinoma and nasopharyngeal carcinoma (reported reactivation rates of 36% and 28.6% respectively) 4,5 . Case reports of hbv reactivation in bladder, pancreatic, and non-small-cell lung cancer have also been reported [16][17][18] (no cohort data are available for those populations). Still, rates of adverse outcomes related to reactivation remain poorly characterized.…”

Section: Discussionmentioning

confidence: 99%

Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement

Lee

Bell

et al. 2010

Current Oncology

View full text Add to dashboard Cite

show abstract

“…The frequency of HBVr is highest during chemotherapy for leukemia or lymphoma, with some reported rates exceeding 50% ( 38 ). HBVr also occurs during anticancer treatment of solid tumors, such as breast cancer ( 39 ), hepatocellular carcinoma ( 40 , 41 ), pancreatic cancer ( 42 ), lung cancer ( 43 ), gastric adenocarcinoma ( 44 ), and pleural carcinoma ( 45 ). Lv et al indicated that the HBVr rate ranges from 0.0–21.4% for different treatments and regimens in patients with NPC, and patients treated with IC alone had a 3.8% risk for reactivation ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

Survival impact of additional induction chemotherapy in nasopharyngeal carcinoma with chronic hepatitis B infection: a retrospective, bi-center study

Chen

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Patients with nasopharyngeal carcinoma (NPC) who have hepatitis B virus (HBV) infection tend to be treated with induction chemotherapy (IC) due to a higher metastasis rate. However, additional IC may lead to immunosuppression and can negatively affect the prognosis. We evaluated whether receiving IC improved the prognosis of patients with NPC co-infected with HBV, on the basis of concurrent chemoradiotherapy (CCRT).Methods: This large-scale retrospective cohort study included data of patients with pathologically confirmed NPC that were collected from two hospitals between January 2010 and March 2014. Patients were followed-up every 3 months during the first 2 years and once every 6 months thereafter. Univariate analysis identified confounding factors associated with prognosis. Stage-based subgroup analyses and 1:1 random-matched pair analyses were performed to compare the survival differences between patients treated with IC + CCRT and those treated with CCRT alone.Results: Among the 1,076 enrolled patients, 16.6% were hepatitis B surface antigen (HBsAg)-positive.Among HBsAg-positive patients with stage II/III/IV NPC, distant metastasis-free survival (DMFS) (79.3% vs. 89.9%; P=0.045) and progression-free survival (PFS) (70.6% vs. 83.7%; P=0.025) were lower in patients who received IC + CCRT than in those who received CCRT alone. After adjusting for confounding factors, IC + CCRT was validated as a negative prognosticator for DMFS and PFS, while matched-pair analysis with HBsAg-negative patients showed a better overall survival (OS) for IC + CCRT (88.4% vs. 82.6%; P=0.04).Conclusions: Compared with CCRT alone, IC + CCRT negatively affects DMFS and PFS in patients with NPC with chronic HBV infection. We advocate withholding IC but administering stronger initial treatment in NPC patients complicated with HBV infection.

show abstract

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

Cited by 16 publications

References 29 publications

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement

Survival impact of additional induction chemotherapy in nasopharyngeal carcinoma with chronic hepatitis B infection: a retrospective, bi-center study

Contact Info

Product

Resources

About